Latest Infant Milk Formula News

Page 1 of 2
The a2 Milk Company has secured key regulatory approvals in China, moving closer to launching its infant formula products under the a2MC brand by mid-2027.
Victor Sage
Victor Sage
24 Nov 2025
The a2 Milk Company has raised its FY26 revenue guidance, citing stronger-than-expected performance in key product categories and favourable currency movements. The company anticipates solid earnings growth and robust cash flow conversion.
Victor Sage
Victor Sage
20 Nov 2025
The a2 Milk Company is expanding its strategic partnership with China State Farm to include English label infant milk formula products, starting with a2 Genesis™ in early 2026. This move aims to strengthen distribution control and capitalize on China’s booming infant formula market.
Victor Sage
Victor Sage
10 Nov 2025
Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.
Victor Sage
Victor Sage
29 Aug 2025
The a2 Milk Company delivered record FY25 results with $1.9 billion in sales and announced a transformative acquisition of a New Zealand manufacturing facility, alongside divesting its stake in Mataura Valley Milk and planning a $300 million special dividend.
Victor Sage
Victor Sage
18 Aug 2025
The a2 Milk Company reported a robust 21% rise in net profit for FY25, driven by strong growth in China and the USA, alongside a landmark full-year dividend declaration and major supply chain restructuring.
Victor Sage
Victor Sage
18 Aug 2025
The a2 Milk Company reported record FY25 results with $1.9 billion in sales and declared its first-ever dividends, while advancing a major supply chain overhaul through a key New Zealand manufacturing acquisition and divestment.
Victor Sage
Victor Sage
18 Aug 2025
Bubs Australia Limited reports a strong FY25 with 29% revenue growth to $102.5 million, positive EBITDA turnaround, and sustained cash flow improvements. The company also advances its US market ambitions with a key FDA submission underway.
Victor Sage
Victor Sage
28 July 2025
Bubs Australia has submitted critical clinical trial data to the US FDA, marking a pivotal step toward permanent approval for its infant formulas in the US market.
Victor Sage
Victor Sage
16 June 2025
The a2 Milk Company posted robust first-half FY25 results, lifting revenue by 10.1% and net profit by 7.6%, while introducing a dividend policy for the first time. Strong English label IMF sales and liquid milk growth underpin an upgraded full-year outlook.
Eva Park
Eva Park
17 Feb 2025
The a2 Milk Company delivered solid first-half FY25 results with revenue up 10.1% and net profit rising 7.6%, driven by strong growth in China and the USA despite supply constraints and ANZ challenges. The company also declared its first-ever interim dividend and upgraded its full-year outlook.
Eva Park
Eva Park
17 Feb 2025
The a2 Milk Company has reported robust first-half FY25 results, boosting full-year guidance and declaring its inaugural dividend, underscoring confidence in its growth trajectory.
Eva Park
Eva Park
17 Feb 2025